SMC accepts fentanyl single dose nasal spray
17th January 2012
The Scottish Medicines Consortium (SMC) has accepted fentanyl single dose nasal spray (Instanyl®, Nycomed) for use within NHS Scotland for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Its use is restricted to patients who are unsuitable for other short-acting oral opioids (e.g. oral morphine) as an alternative to other buccal and sublingual fentanyl preparations.
Recent news
- SMC accepts fentanyl single dose nasal spray
- NICE end of life care commissioning guide
- AWMSG approve tapentadol m/r for restricted use
- US FDA approve fentanyl sublingual spray
- NPSA Rapid Response Report on spinal connectors
- Update: anti-epileptics monograph
- NPC review m/r oxycodone/naloxone
- Prednisolone EC blister packs recalled from Teva
- Citalopram and escitalopram maximum daily doses restricted
- Extemporaneous thalidomide oral suspension stability study
News archive
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000